治疗骨质疏松症新药:romosozumab

New drug for osteoporosis: romosozumab

romosozumab是一种IgG2人源化单克隆抗体,可以结合和抑制硬化蛋白,促进骨形成,减少骨吸收,改善骨密度,降低骨折发生率,具有良好的可耐受性。该药已被欧盟、澳大利亚、加拿大、日本、韩国和美国批准用于治疗骨折风险较高的骨质疏松症患者。本文对该药的作用机制、药动学特征、临床疗效、安全性、用法用量等方面进行综述。

Romosozumab is an IgG2 humanized monoclonal antibody that binds and inhibits sclerostin.It is a boneforming antibody that can increase bone formation,decrease bone resorption,improve bone mineral density,and decrease fracture rates,with well tolerance.Romosozumab has been approved for the treatment of osteoporosis in patients at high risk of fracture in the European Union,Australia,Canada,Japan,South Korea and the USA.The mechanism of action,pharmacokinetic characteristics,clinical efficacy,safety,dosage and other aspects of the drug were reviewed in this paper.